PT2836491T - Forma salina de um inibidor da histona metiltransferase humana ezh2 - Google Patents

Forma salina de um inibidor da histona metiltransferase humana ezh2

Info

Publication number
PT2836491T
PT2836491T PT137749792T PT13774979T PT2836491T PT 2836491 T PT2836491 T PT 2836491T PT 137749792 T PT137749792 T PT 137749792T PT 13774979 T PT13774979 T PT 13774979T PT 2836491 T PT2836491 T PT 2836491T
Authority
PT
Portugal
Prior art keywords
salt form
histone methyltransferase
ezh2 inhibitor
human histone
methyltransferase ezh2
Prior art date
Application number
PT137749792T
Other languages
English (en)
Inventor
Wayne Kuntz Kevin
Huang Kuan-Chun
Wook Choi Hyeong
Sanders Kristen
Mathieu Steven
Chanda Arani
Fang Frank
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of PT2836491T publication Critical patent/PT2836491T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PT137749792T 2012-04-13 2013-04-11 Forma salina de um inibidor da histona metiltransferase humana ezh2 PT2836491T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13

Publications (1)

Publication Number Publication Date
PT2836491T true PT2836491T (pt) 2017-02-08

Family

ID=49328166

Family Applications (3)

Application Number Title Priority Date Filing Date
PT191804798T PT3628670T (pt) 2012-04-13 2013-04-11 Forma salina de um inibidor de ezh2
PT16191716T PT3184523T (pt) 2012-04-13 2013-04-11 Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico
PT137749792T PT2836491T (pt) 2012-04-13 2013-04-11 Forma salina de um inibidor da histona metiltransferase humana ezh2

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT191804798T PT3628670T (pt) 2012-04-13 2013-04-11 Forma salina de um inibidor de ezh2
PT16191716T PT3184523T (pt) 2012-04-13 2013-04-11 Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico

Country Status (25)

Country Link
US (6) US9394283B2 (pt)
EP (4) EP3628670B1 (pt)
JP (3) JP6255382B2 (pt)
KR (3) KR20220123339A (pt)
CN (2) CN108358899B (pt)
AU (2) AU2013245878B2 (pt)
BR (1) BR112014025508B1 (pt)
CA (1) CA2870005C (pt)
CY (2) CY1119383T1 (pt)
DK (3) DK2836491T3 (pt)
ES (3) ES2617379T3 (pt)
HR (2) HRP20170295T1 (pt)
HU (3) HUE060881T2 (pt)
IL (4) IL296199A (pt)
IN (1) IN2014DN09068A (pt)
LT (2) LT3184523T (pt)
MX (1) MX362339B (pt)
NZ (1) NZ700761A (pt)
PL (3) PL3184523T3 (pt)
PT (3) PT3628670T (pt)
RS (2) RS55690B1 (pt)
RU (1) RU2658911C2 (pt)
SG (3) SG10201912109QA (pt)
SI (2) SI2836491T1 (pt)
WO (1) WO2013155317A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3628670B1 (en) 2012-04-13 2022-10-12 Epizyme, Inc. Salt form for ezh2 inhibition
KR20200062386A (ko) 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
RU2658919C2 (ru) * 2012-10-15 2018-06-26 Эпизайм, Инк. Замещенные бензольные соединения
EP3659606A1 (en) * 2012-10-15 2020-06-03 Epizyme, Inc. Methods of treating cancer
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
MX2015015144A (es) 2013-04-30 2016-02-18 Glaxosmithkline Ip No 2 Ltd Potenciador de inhibidores del homologo de zeste.
RU2016104044A (ru) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед Ингибиторы усилителя zeste гомолога 2
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
SG10201901977XA (en) 2013-10-16 2019-04-29 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
KR102473113B1 (ko) 2013-12-06 2022-12-01 에피자임, 인코포레이티드 암 치료를 위한 병용 요법
KR102497728B1 (ko) 2014-06-17 2023-02-09 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
JP6682522B2 (ja) 2014-06-20 2020-04-15 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ２−（（４ｓ）−６−（４−クロロフェニル）−１−メチル−４ｈ−ベンゾ［ｃ］イソオキサゾロ［４，５−ｅ］アゼピン−４−イル）アセトアミドの結晶形態
MX2017004969A (es) 2014-10-16 2017-07-19 Epizyme Inc Metodo para tratar el cancer.
PL3220916T3 (pl) 2014-11-17 2023-08-14 Epizyme, Inc. Sposób leczenia raka n-((4,6-dimetylo-2-okso-1,2-dihydropirydyn-3-ylo)metylo)-5-(etylo(tetrahydro-2h-piran-4-ylo)amino)-4-metylo-4'-(morfolinometylo)-[1,1'-bifenylo]-3-karboksyamidem
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
EP3341080A4 (en) 2015-08-24 2019-03-20 Epizyme Inc METHOD FOR THE TREATMENT OF CANCER
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
US11951108B2 (en) 2016-01-29 2024-04-09 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
CN110191879A (zh) * 2017-01-25 2019-08-30 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
JP2023509385A (ja) 2019-12-20 2023-03-08 エピザイム インコーポレイテッド Ｅｚｈ２阻害剤の結晶性ヒドロブロミド塩、その調製及びがんの治療に有用な医薬組成物
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
ATE180468T1 (de) 1993-12-27 1999-06-15 Eisai Co Ltd Anthranilsäure derivate
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
ES2330719T3 (es) 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
DE60329981D1 (de) 2002-02-19 2009-12-24 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
CN1989131A (zh) * 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
DE602005017781D1 (de) 2004-06-01 2009-12-31 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1891434B1 (en) 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
ES2416336T3 (es) 2005-10-19 2013-07-31 Grünenthal GmbH Nuevos ligandos del receptor vanilloide y su uso para la producción de medicamentos
CA2626402C (en) 2005-10-21 2011-02-15 Merck & Co., Inc. Potassium channel inhibitors
EP1941060B1 (en) 2005-10-28 2012-02-29 The University of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
KR20080080173A (ko) 2005-12-14 2008-09-02 브리스톨-마이어스 스큅 컴퍼니 세린 프로테아제 억제제로서 유용한 6-원 헤테로사이클
EP2730661A1 (en) 2006-01-20 2014-05-14 The University of North Carolina at Chapel Hill Diagnostic and therapeutic targets for leukemia
JP2009537521A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー テレフタラメート化合物および組成物、ならびにｈｉｖインテグラーゼ阻害剤としてのそれらの使用
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US8198279B2 (en) 2007-12-19 2012-06-12 Institute Of Cancer Research: Royal Cancer Hospital (The) Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
JP5548197B2 (ja) 2008-08-08 2014-07-16 ニューヨーク ブラッド センター， インコーポレイテッド レトロウイルスの集合及び成熟の小分子阻害剤
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2521558A4 (en) 2009-12-30 2013-07-03 Avon Prod Inc TOPICAL LIGHTING COMPOSITION AND USES THEREOF
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
NZ603454A (en) * 2010-05-07 2014-06-27 Glaxosmithkline Llc Indoles useful for treating cellular proliferation diseases such as cancer
KR102511807B1 (ko) 2010-09-10 2023-03-20 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
ES2718900T3 (es) 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
EP3628670B1 (en) 2012-04-13 2022-10-12 Epizyme, Inc. Salt form for ezh2 inhibition
KR20200062386A (ko) 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP3659606A1 (en) 2012-10-15 2020-06-03 Epizyme, Inc. Methods of treating cancer
SG10201901977XA (en) 2013-10-16 2019-04-29 Epizyme Inc Hydrochloride salt form for ezh2 inhibition

Also Published As

Publication number Publication date
US20230140327A1 (en) 2023-05-04
AU2013245878A1 (en) 2014-10-30
US10245269B2 (en) 2019-04-02
HUE031976T2 (en) 2017-08-28
EP4190777A1 (en) 2023-06-07
EP3628670A1 (en) 2020-04-01
CY1119383T1 (el) 2018-02-14
US20150065503A1 (en) 2015-03-05
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
PT3628670T (pt) 2022-12-02
CN108358899B (zh) 2021-07-27
IL235045B (en) 2019-05-30
MX2014012380A (es) 2015-07-23
ES2617379T3 (es) 2017-06-16
DK3628670T3 (da) 2022-12-05
SG11201406468YA (en) 2015-01-29
IL282732B2 (en) 2023-04-01
DK2836491T3 (en) 2017-03-06
US9872862B2 (en) 2018-01-23
HUE045353T2 (hu) 2019-12-30
HUE060881T2 (hu) 2023-04-28
US10821113B2 (en) 2020-11-03
US11491163B2 (en) 2022-11-08
PL3628670T3 (pl) 2023-02-20
KR20150002730A (ko) 2015-01-07
AU2018200168A1 (en) 2018-02-01
AU2018200168B2 (en) 2019-08-29
IL296199A (en) 2022-11-01
IL266165B (en) 2021-06-30
KR102438340B1 (ko) 2022-08-30
DK3184523T3 (da) 2019-08-19
IN2014DN09068A (pt) 2015-05-22
US20190269692A1 (en) 2019-09-05
RU2014145544A (ru) 2016-06-10
EP3628670B1 (en) 2022-10-12
JP2018199740A (ja) 2018-12-20
IL282732B (en) 2022-12-01
SG10201912109QA (en) 2020-02-27
SG10201608577RA (en) 2016-12-29
CY1122883T1 (el) 2022-03-24
HRP20191653T1 (hr) 2020-02-21
HRP20170295T1 (hr) 2017-04-21
KR20200066380A (ko) 2020-06-09
EP2836491B1 (en) 2016-12-07
RU2658911C2 (ru) 2018-06-26
AU2013245878B2 (en) 2017-10-12
ES2931316T3 (es) 2022-12-28
LT3184523T (lt) 2020-02-10
ES2745016T3 (es) 2020-02-27
IL235045A0 (en) 2014-12-31
WO2013155317A1 (en) 2013-10-17
US20170143729A1 (en) 2017-05-25
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
CA2870005C (en) 2021-06-22
MX362339B (es) 2019-01-11
PL2836491T3 (pl) 2017-08-31
EP3184523B1 (en) 2019-06-19
CN104603130A (zh) 2015-05-06
RS55690B1 (sr) 2017-07-31
SI3184523T1 (sl) 2020-04-30
US20180243316A1 (en) 2018-08-30
NZ700761A (en) 2016-09-30
IL282732A (en) 2021-06-30
JP6255382B2 (ja) 2017-12-27
SI2836491T1 (sl) 2017-06-30
EP3184523A1 (en) 2017-06-28
US20210137936A1 (en) 2021-05-13
JP6634058B2 (ja) 2020-01-22
KR102120883B1 (ko) 2020-06-09
RS59392B1 (sr) 2019-11-29
US9394283B2 (en) 2016-07-19
CN108358899A (zh) 2018-08-03
JP2015512942A (ja) 2015-04-30
KR20220123339A (ko) 2022-09-06
CN104603130B (zh) 2018-04-27
PT3184523T (pt) 2019-09-26
JP2018002742A (ja) 2018-01-11
PL3184523T3 (pl) 2019-12-31
LT2836491T (lt) 2017-03-27
EP2836491A4 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
LT2836491T (lt) Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma
IL253259A0 (en) Inhibitors of histone demethylases
EP2701699A4 (en) INHIBITORS OF HISTONE DEACETYLASE
PT2680694T (pt) Inibidores de histona deacetilase
AP3268A (en) Co-crystals and salts of CCR3-inhibitors
EP2914298A4 (en) Inhibition of histone metyltransferase for cardiac remission
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2683402A4 (en) VACCINATION METHOD INVOLVING HISTONE DEACETYLASE INHIBITOR
EP2939668A4 (en) PDK4 INHIBITOR AND USE THEREOF
EP2838528A4 (en) METHODS OF INHIBITING SHC-1 / P66 TO COMBAT AGING-RELATED DISEASES
PL2709584T3 (pl) Zastosowanie sensoryczne pochodnych 6-cyklopentylidenoheksanu
HK1247920A1 (zh) 組蛋白去甲基化酶抑制劑
ZA201308872B (en) Use of a dinitromethane salt
ZA201205358B (en) Use of a salt of bistetrazolylamine